Inhaled Amikacin Reduces Ventilatory-Associated Pneumonia
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 30, 2023 -- For critically ill patients undergoing mechanical ventilation for at least three days, a three-day course of inhaled amikacin reduces the subsequent burden of ventilatory-associated pneumonia, according to a study published online Oct. 25 in the New England Journal of Medicine. The study was published to coincide with the annual congress of the European Society of Intensive Care Medicine, held from Oct. 21 to 25 in Milan.
Stephan Ehrmann, M.D., Ph.D., from the Centre Hospitalier Régional Universitaire de Tours in France, and colleagues conducted a multicenter superiority trial involving critically ill adults who had been undergoing invasive mechanical ventilation for at least 72 hours to receive inhaled amikacin once daily or placebo for three days (417 and 430 patients, respectively). Overall, 337 and 355 patients (81 and 82 percent) received all three daily nebulizations in the amikacin and placebo groups, respectively.
The researchers found that ventilator-associated pneumonia developed at day 28 in 15 percent of patients in the amikacin group and 22 percent in the placebo group (difference in restricted mean survival time to ventilator-associated pneumonia, 1.5 days). In 18 and 26 percent of the patients in the amikacin and placebo groups, respectively, an infection-related ventilator-associated complication occurred (hazard ratio, 0.66). Overall, 1.7 percent of patients in the amikacin group and 0.9 percent in the placebo group had trial-related serious adverse effects.
"In this large multicenter trial, a three-day course of amikacin reduced the burden of ventilator-associated pneumonia by day 28 as compared with placebo," the authors write. "Results were consistent with regard to ventilator-associated events."
Several authors disclosed ties to industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Inappropriate Diagnosis of Pneumonia Common in Hospitalized Adults
WEDNESDAY, March 27, 2024 -- Inappropriate diagnosis of community-acquired pneumonia (CAP) in hospitalized adults is common, especially among older adults and those with dementia...
Hispanic Patients More Likely to Receive Deep Sedation While on Ventilator
TUESDAY, Feb. 27, 2024 -- Hispanic individuals who are hospitalized with respiratory failure have a higher risk for receiving deep sedation while on a ventilator than non-Hispanic...
Percentage of Mycoplasma Pneumoniae Infections Up Since September 2023
THURSDAY, Feb. 22, 2024 -- The percentage of Mycoplasma pneumoniae infections decreased during the pandemic, but has increased since September 2023, according to research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.